Enanta Pharmaceuticals Reports $65.3 Million Revenue for Fiscal Year Ending September 30, 2025

Enanta Pharmaceuticals, Inc. reported a total revenue of $65.3 million for the fiscal year ending September 30, 2025, a decrease from $67.6 million in the previous year. This decline is primarily attributed to lower sales of AbbVie’s MAVYRET/MAVIRET regimen, which includes Enanta's protease inhibitor, glecaprevir, for the treatment of hepatitis C virus (HCV). The company noted that 54.5% of its reported revenues now go directly to OMERS following a royalty sale agreement made in April 2023, which has capped future royalty payments at 1.42 times the purchase price. Enanta anticipates continued operating losses due to the dependency on AbbVie’s sales performance and the ongoing costs associated with its research and development programs.

Research and development expenses for the year were $106.7 million, down from $131.5 million in 2024, reflecting a decrease in costs associated with clinical trials for its respiratory syncytial virus (RSV) programs. The company is also advancing its immunology programs, which saw an increase in expenses as it focuses on developing oral small molecule inhibitors targeting type 2 inflammatory diseases. General and administrative expenses decreased to $43.9 million from $57.9 million, largely due to reduced legal expenses related to ongoing patent litigation.

As of September 30, 2025, Enanta had $188.9 million in cash, cash equivalents, and short-term marketable securities, which it believes will fund operations into fiscal 2029. The company completed a public offering in October 2025, raising approximately $74.8 million, which will support its ongoing development efforts. However, Enanta acknowledges the need for substantial additional funding to achieve its long-term goals, particularly as it continues to invest in its proprietary product candidates.

Enanta's strategic focus includes advancing its clinical-stage programs for RSV and other viral infections, as well as its immunology pipeline targeting chronic spontaneous urticaria and atopic dermatitis. The company is also exploring partnership opportunities to enhance the development of its RSV programs. However, it faces significant competition in these therapeutic areas, which could impact its ability to successfully commercialize its product candidates.

Looking ahead, Enanta's financial outlook remains cautious, with expectations of continued operating losses and reliance on AbbVie’s sales performance for revenue generation. The company is actively assessing its research and development strategies and may adjust its focus based on the evolving landscape of the biopharmaceutical industry and the competitive environment for its product candidates.